Ingenuity Systems has extended and expanded its existing license agreement with GlaxoSmithKline for access to Ingenuity Pathways Analysis (IPA) software.
The new agreement enables GSK to provide enterprise-wide IPA access to researchers for rapid assessment of the signalling and metabolic pathways, molecular networks, and biological processes that are most significant to disease targets. In addition, GSK will also use Ingenuity's content and proprietary algorithms.
